UK: Pheon completes US$120m Series B to fund ADC pipeline development

Pheon Therapeutics, an Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, has completed a US$120m Series B financing to fund the development of […]